GENESIS: Genotype Guided - Natriuretic Peptides - Cardiometabolic Health Study
Atrial Natriuretic Peptide and Regulation of Cardiometabolic Health: A Genotype-Guided Human Physiological Study
University of Alabama at Birmingham
200 participants
Apr 1, 2022
INTERVENTIONAL
Conditions
Summary
Natriuretic Peptides (NP) are hormones produced by the heart, and they have a wide range of favorable metabolic benefits. Lower levels of these hormones are associated with an increased likelihood of the development of diabetes and poor cardiometabolic health. Obese and Black individuals have \~30% lower levels of NP and are at a greater risk of developing cardiovascular (CV) events as compared to lean and White counterparts. Some people have common genetic variations that cause them to have \~20% lower NP levels. Similar to other low NP populations, these individuals with low NP genotype (i.e., carrying a common genetic variation called rs5068) are at a greater risk of developing cardiometabolic diseases. By understanding the NP response following the exercise challenge and the glucose challenge in individuals with genetically lower NP levels will help us understand how to improve cardiometabolic health in them.
Eligibility
Inclusion Criteria3
- Adults: Age more than or equal to 18; an equal number of Males and Females
- Consent to the collection of genetic material
- Willing to adhere to the study protocol
Exclusion Criteria11
- Age \<18, at screening.
- BMI \>45 kg/m2.
- Blood pressure more than 140/90 mmHg.
- Participants who are taking more than 2 hypertension medications.
- History of diabetes or fasting plasma glucose \>126 mg/dl or HbA1C\>=6.5% or prior treatment with antidiabetic medication.
- Have any past or present history of cardiovascular diseases (stroke, seizure, myocardial infarction, heart failure, transient ischemic attack, angina, or cardiac arrhythmia)
- Women who are pregnant or breastfeeding or who can become pregnant and not practicing an acceptable method of birth control during the study (including abstinence);
- Estimated GFR \< 60 ml/min/1.73 m2; albumin creatinine ratio ≥30 mg/g
- Hepatic Transaminase (AST and ALT) levels \>3x the upper limit of normal
- Anemia (men, Hct \< 38%; women, Hct \<36%)
- Inability to exercise on a treadmill
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants will consume the study diet for 5 days provided by the clinical research unit's metabolic kitchen (at UAB)
Each participant's maximal oxygen capacity will be determined using a modified Bruce treadmill protocol and will also undergo a DEXA scan to determine the body mass.
Each participant will walk at 70 % of his/her VO2max for 20 minutes on treadmill and will also undergo a resting energy expenditure test.
Participants will come in fasting state on day 6th and will be given 75 gm oral glucose solution to drink, followed by blood collection every hour for next 8 hours.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05216042